AXGN

Company Overview — What Does Axogen, Inc. Do?

AxoGen, Inc., together with its subsidiaries, develops and markets surgical solutions for physical damage or transection to peripheral nerves. The company's products include Avance Nerve Graft, a biologically active off-the-shelf processed human nerve allograft for bridging severed nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed peripheral nerves; and AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect damaged peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue attachments. Its products also comprise Axoguard Nerve Cap, a porcine submucosa ECM product that is used to protect a peripheral nerve end, as well as separates the nerve from the surrounding environment to reduce the development of symptomatic or painful neuroma; and Avive Soft Tissue Membrane, a processed human umbilical cord membrane that can be used as a resorbable soft tissue covering to separate tissues in the surgical bed. In addition, the company offers AxoTouch two point discriminator, a tool that is used for measuring the innervation density of surface area of the skin. It provides its products to hospitals, surgery centers, and military hospitals plastic reconstructive surgeons, orthopedic and plastic hand surgeons, and various oral and maxillofacial surgeons in the United States, Canada, Germany, the United Kingdom and other European countries, South Korea, and internationally. AxoGen, Inc. is headquartered in Alachua, Florida. Axogen, Inc. (AXGN) is classified as a small-cap stock in the Healthcare sector, specifically within the Medical Equipment industry. The company is led by CEO Karen L. Zaderej and employs approximately 450 people, headquartered in ALACHUA, Florida. With a market capitalization of $1.7B, AXGN is one of the notable companies in the Healthcare sector.

Axogen, Inc. (AXGN) Stock Rating — Hold (April 2026)

As of April 2026, Axogen, Inc. receives a Hold rating with a composite score of 44.0/100 and 3 out of 5 stars from the Blank Capital Research quantitative model.AXGN ranks #735 out of 4,446 stocks in our coverage universe. Within the Healthcare sector, Axogen, Inc. ranks #51 of 838 stocks, placing it in the top 10% of its Healthcare peers. The rating is generated by a multi-factor model that weighs quality (30%), momentum (25%), value (15%), investment (10%), stability (10%), and short interest (10%).

AXGN Stock Price and 52-Week Range

Axogen, Inc. (AXGN) currently trades at $32.59. The stock lost $0.43 (1.3%) in the most recent trading session. The 52-week high for AXGN is $36.00, which means the stock is currently trading -9.5% from its annual peak. The 52-week low is $9.21, putting the stock 253.7% above its annual trough. Recent trading volume was 633K shares, suggesting relatively thin trading activity.

Is AXGN Overvalued or Undervalued? — Valuation Analysis

Axogen, Inc. (AXGN) carries a value factor score of 35/100 in the Blank Capital model, signaling premium valuation that prices in significant future growth. The price-to-book ratio stands at 12.48x, versus the sector average of 2.75x. The price-to-sales ratio is 7.52x, compared to 1.66x for the average Healthcare stock. On an enterprise value basis, AXGN trades at 1030.92x EV/EBITDA, versus 6.34x for the sector.

At current multiples, Axogen, Inc. trades at a premium to most Healthcare peers. This elevated valuation may be justified if the company can sustain above-average growth rates and profitability, but it also creates downside risk if earnings disappoint expectations.

Axogen, Inc. Profitability — ROE, Margins, and Quality Score

Axogen, Inc. (AXGN) earns a quality factor score of 42/100, signaling below-average profitability metrics relative to the broader market. The return on equity (ROE) is -3.4%, compared to the Healthcare sector average of -43.5%, which is below typical expectations for high-quality companies. Return on assets (ROA) comes in at -2.0% versus the sector average of -33.1%.

On a margin basis, Axogen, Inc. reports gross margins of 74.4%, compared to 71.5% for the sector. The operating margin is 0.5% (sector: -66.1%). Net profit margin stands at -2.4%, versus -58.7% for the average Healthcare stock. Revenue growth is running at 25.4% on a trailing basis, compared to 10.6% for the sector. Profitability is below benchmark levels, which may reflect industry headwinds, elevated reinvestment, or structural challenges.

AXGN Debt, Balance Sheet, and Financial Health

Axogen, Inc. has a debt-to-equity ratio of 38.0%, compared to the Healthcare sector average of 32.0%. The low leverage indicates a conservative balance sheet with significant financial flexibility. The current ratio is 5.11x, indicating strong short-term liquidity. Total debt on the balance sheet is $48M. Cash and equivalents stand at $24M.

AXGN has a beta of 1.08, meaning it is roughly in line with the broader market in terms of price volatility. The stability factor score for Axogen, Inc. is 48/100, reflecting average volatility within the normal range for its sector.

Axogen, Inc. Revenue and Earnings History — Quarterly Trend

In TTM 2026, Axogen, Inc. reported revenue of $214M and earnings per share (EPS) of $-0.34. Net income for the quarter was $-4M. Gross margin was 74.4%. Operating income came in at $2M.

In FY 2025, Axogen, Inc. reported revenue of $225M and earnings per share (EPS) of $-0.34. Net income for the quarter was $-16M. Gross margin was 74.3%. Revenue grew 20.2% year-over-year compared to FY 2024. Operating income came in at $-8M.

In Q3 2025, Axogen, Inc. reported revenue of $60M and earnings per share (EPS) of $0.02. Net income for the quarter was $708,000. Gross margin was 76.5%. Revenue grew 23.5% year-over-year compared to Q3 2024. Operating income came in at $2M.

In Q2 2025, Axogen, Inc. reported revenue of $57M and earnings per share (EPS) of $0.01. Net income for the quarter was $579,000. Gross margin was 74.2%. Revenue grew 18.3% year-over-year compared to Q2 2024. Operating income came in at $2M.

Over the past 8 quarters, Axogen, Inc. has demonstrated a growth trajectory, with revenue expanding from $48M to $214M. Investors analyzing AXGN stock should weigh these quarterly trends alongside the valuation and quality metrics discussed above.

AXGN Dividend Yield and Income Analysis

Axogen, Inc. (AXGN) does not currently pay a dividend. This is common among smaller companies in the Medical Equipment industry that prefer to reinvest cash flows into business expansion rather than returning capital to shareholders. Income-focused investors looking for Healthcare dividend stocks may want to explore other Healthcare stocks or use the stock screener to filter by dividend yield.

AXGN Momentum and Technical Analysis Profile

Axogen, Inc. (AXGN) has a momentum factor score of 67/100, reflecting neutral trend characteristics. The stock is neither significantly outperforming nor underperforming the broader market on a momentum basis. The investment factor score is 25/100, which measures capital allocation efficiency and asset growth patterns. The short interest score of 22/100 signals elevated short interest, which can indicate bearish sentiment among institutional investors.

AXGN vs Competitors — Healthcare Sector Ranking and Peer Comparison

Within the Healthcare sector, Axogen, Inc. (AXGN) ranks #51 out of 838 stocks based on the Blank Capital composite score. This places AXGN in the top decile of all Healthcare stocks in our coverage universe. Key competitors and sector peers include ASTRAZENECA PLC (AZN) with a score of 61.4/100, Sol-Gel Technologies Ltd. (SLGL) with a score of 56.6/100, VIEMED HEALTHCARE, INC. (VMD) with a score of 53.4/100, Innoviva, Inc. (INVA) with a score of 52.7/100, and JOHNSON & JOHNSON (JNJ) with a score of 51.7/100.

Comparing AXGN against the S&P 500 benchmark is also instructive for understanding relative performance. Investors can view the full AXGN vs S&P 500 (SPY) comparison to assess how Axogen, Inc. stacks up against the broader market across all factor dimensions.

AXGN Next Earnings Date

No upcoming earnings date has been announced for Axogen, Inc. (AXGN) at this time. Check the earnings calendar for the latest scheduling updates across all stocks in our coverage universe.

Should You Buy AXGN? — Investment Thesis Summary

Axogen, Inc. presents a balanced picture with arguments on both sides. The value score of 35/100 indicates premium valuation. Price momentum is positive at 67/100, suggesting the trend favors buyers.

In summary, Axogen, Inc. (AXGN) earns a Hold rating with a composite score of 44.0/100 as of April 2026. The rating is derived from the Blank Capital Research methodology, which combines six factor dimensions into a single quantitative ranking. Investors should consider these quantitative signals alongside their own fundamental research, risk tolerance, and investment time horizon before making buy or sell decisions on AXGN stock.

Related Resources for AXGN Investors

Explore more research and tools: AXGN vs S&P 500 comparison, top Healthcare stocks, stock screener, our methodology, quality factor explained, value factor explained, momentum factor explained. Compare AXGN head-to-head with peers: AXGN vs AZN, AXGN vs SLGL, AXGN vs VMD.